Actinogen is developing a revolutionary oral therapeutic, Xanamem^®, which controls levels of the “stress hormone” cortisol in the brain, with the goal of improving the lives of patients and their families. Topline results from our first pivotal Alzheimer’s trial, evaluating its potential to slow disease progression, are expected in November 2026.

FY 2026 financial results - pivotal Alzheimer’s trial results imminent

FY26 Appendix 4E and annual report

Access our FY26 Appendix 4E and Annual Report, providing a comprehensive overview of financial and operational performance for the year ended 30 June 2026.

ACW Presents at Bioshares Summit 2026

Actinogen presented a corporate presentation highlighting Xanamem® and its scientific rationale in Alzheimer’s disease. The presentation explores the role of cortisol in the brain and Xanamem®’s potential to reduce elevated cortisol through inhibition of the 11β-HSD1 enzyme.

Clinical Trial Science Forum Webinar - 12 August 2026

Join Actinogen for a live webinar exploring the future of Alzheimer’s treatment, featuring expert perspectives from Dr Marwan Sabbagh and Actinogen’s Chief Medical Officer, Dr Dana Hilt on Wednesday 12 August 2026 at 11am AEST. The discussion will cover evolving treatment approaches, anti-amyloid therapies, blood-based biomarkers and next-generation Alzheimer’s therapies.

ACW June 2026 quarterly activity report & Appendix 4C

Actinogen has released its quarterly activity report and Appendix 4C for the three-month period ended 30 June 2026.

Xanamem Depression Trial Published in British Journal of Psychiatry

Actinogen announces that results from its proof-of-concept trial, entitled “A phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder (MDD) and cognitive impairment (CI)” has been published as a peer-reviewed article in the prestigious British Journal of Psychiatry.